WAYNE, Pa. (AP) _ Aclaris Therapeutics Inc. (ACRS) on Friday reported a loss of $31.2 million in its second quarter.

The Wayne, Pennsylvania-based company said it had a loss of $1.01 per share.

The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 95 cents per share.

The specialty pharmaceutical company posted revenue of $3.7 million in the period, beating Street forecasts. Three analysts surveyed by Zacks expected $2.8 million.

Aclaris shares have declined 27 percent since the beginning of the year. The stock has declined 35 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ACRS at https://www.zacks.com/ap/ACRS